NHS 쾌속정 데이터는 비용 절감을 보여줍니다.
크레오 메디컬 그룹 plc
("Creo"는 "회사" 또는 "그룹")
NHS Supply Chain real-world data demonstrates substantial cash savings and operational benefits from Speedboat Submucosal Dissection (SSD) procedures
Case study by an NHS Trust sets out the cash savings and operational benefits gained from the use of Creo's Speedboat technology for bowel SSD procedures, in addition to life changing clinical outcomes for patients
Creo Medical Group plc (AIM: CREO), the medical device company focused on the emerging field of minimally invasive surgical endoscopy, announces that NHS Supply Chain data demonstrates significant cost and operational savings provided by the use of Creo's Speedboat technology in Speedboat Submucosal Dissection ("SSD") procedures. This is in addition to life changing patient outcomes previously identified by the Company and the ability to positively impact NHS waiting lists.
By analysing 130 SSD patient procedures undertaken at East Kent University Hospitals Foundation Trust ("EKHUFT") as part of their bowel cancer and therapeutic endoscopy service, and comparing against a similar analysis of surgical alternatives, the data confirmed includes:
· 87% reduction in the average length of stay from 8.39 days to 1.07 days;
· 99% reduction in critical care costs;
· 91% reduction in accommodation costs per patient from £3.4k to £0.3k;
· 62% reduction in admission costs from £8.2k to £3.1k;
· Over a 1-year period, costs were reduced from £8.8k to £3.6k (59% reduction);
· Theatre procedure cost reduced from £4.5k to £2.8k (38% reduction);
· Net cash savings from just these 130 patient procedures of £687k realised for the NHS Trust.
The net cash savings referenced were calculated over a one-year period and relate only to the SSD procedure element, and do not include additional benefits and costs savings previously identified and reported by the Company utilising the lifetime horizon Markov model, which included downstream costs associated with recurrence of lesions and procedure-related complications commonly associated with surgical alternatives to SSD.
NHS Supply Chain manages the sourcing, delivery and supply of healthcare products, services and food for NHS Trusts and healthcare organisations across England and Wales. Against the backdrop of ever increasing demands on the NHS and finite financial and operational resources, NHS Supply Chain has embarked on a value based procurement project to work with industry to consider technologies that can influence a reduction in total costs within the patient pathway.
Working with EKHUFT, NHS Supply Chain's Value Based Procurement team's case study found that: "the use of SSD, when compared to surgical alternatives, results in a less invasive procedure for patients whilst maintaining an en-bloc resection with clear margins. The endoscopic nature of the procedure and Speedboat's advanced energy modalities makes this procedure both safe and effective whilst simultaneously reducing time spent in hospital and providing cost benefits in terms of the material and resourcing costs associated with each procedure."
그것은 계속되었다 :
"Using financial modelling on the data generated, EKHUFT has been able to evidence that the adoption of this novel technology and its implementation as part of a new service has resulted in significant savings for the Trust. The detailed dataset will also enable statistical analysis and health economics evaluations to be successfully undertaken with confidence."
The data is the first like-for-like, real-world comparative health economic data provided on the service facilitated by Creo's Speedboat technology. It has been calculated using official NHS data with the analysis conducted using NHS England 'Approved Costing Guidance', recognised by all NHS Trusts in addition to industry bodies and includes a breakdown of all comparators, from theatre time to accommodation cost. The data and associated benefits have been captured as part of an official NHS Supply Chain case study promoting innovative technology and how technology can drive NHS savings.
The full case study and a breakdown of results will be published on the NHS Supply Chain website, and NHS Supply Chain will actively work to promote the value proposition of Creo's Speedboat technology by engaging directly with financial controllers and decision makers at NHS Trusts around the country. The case study will also be shared with the Department of Health and Social Care, NICE and others to illustrate the scope and speed of impact Creo's Speedboat technology can have, not only on patients and clinicians but on healthcare providers.
Creo has previously received a series of awards from the National Institute for Health and Care Research (NIHR) Invention for Innovation (i4i) Programme to support certain development projects, including the development of Speedboat, which targets innovative technology, with a clear path to commercialisation, that can improve patient outcomes and simultaneously reduce cost. This latest published data from NHS Supply Chain not only reinforces NIHR's investment decision to support Creo in the development of its Speedboat technology, but clearly illustrates how such investment benefits patients, healthcare providers and the NHS by enabling the development of solutions to address existing and/or emerging health or social care needs.
Craig Gulliford, Chief Executive Officer of Creo Medical, said: "For NHS Supply Chain to recognise Creo's Speedboat technology as one of just a handful of cutting-edge technologies from so many indications across the NHS is great recognition in itself. The clinical data clearly demonstrates the level of value Speedboat can bring to the NHS and its patients, in-line with our own previous estimates, which is both gratifying and hugely significant.
"With this data, no longer based on modelling, but gained by looking at every aspect of a comprehensive data set of real cases, we look forward to working closely with NHS Supply Chain to ensure that the successes seen in East Kent University Hospitals with Speedboat are replicated in healthcare settings across the UK. This will enable us to continue to impact on patients and also reducing waiting lists significantly with the level of efficiency improvements this data demonstrates."
Sandra Owen, Clinical Engagement & Implementation Manager at NHS Supply Chain, said: "NHS Supply Chain is working on a project designed to consider the potential benefits and practical application of Value Based Procurement (VBP). Here, there is a shift in emphasis from a reduction in product costs to working with industry to consider technologies that can influence a reduction in total costs within the patient pathway, and Speedboat is a good example of this."
Elisa Llewellyn, Director of Commissioning, Contracting and Costing at EKUFT, said: "The introduction of this service at East Kent and the pathway it facilitates have immediately had a positive impact not only in terms of patient outcomes but also from a value perspective. With over 200 Speedboat Submucosal Dissection cases now completed at East Kent, our in-depth costing work clearly shows tangible and consistent financial benefits largely stemming from a reduction in the time patients are spending in hospital as a result of our ability to re-direct patients from surgical waiting lists to our excellent endoscopy unit."
문의 :
크레오 메디컬 그룹 plc | www.creedical.com |
리차드 리스(CFO) | +44 (0)1291 606 005 |
캐번디시 캐피털 마켓 리미티드 | +44 (0)20 7397 8900 |
스티븐 키스 / 카밀라 흄(NOMAD) | |
마이클 존슨(영업) | |
도이치 누미스(공동 Broker) 프레디 반필드 / 던컨 몬테이스 / 유안 브라운 | +44 (0)20 7260 1000 |
월브룩 홍보 | 전화 번호 : +44 (0) 20 7933 8780 or [이메일 보호] |
폴 맥마누스 / 샘 앨런 필립 결혼 | 몹: +44 (0)7980 541 893 / +44 (0)7502 558 258 +44 (0)7867 984 082 |
Creo Medical 정보
Creo Medical은 최소 침습 전기 수술 장치의 개발 및 상용화에 주력하는 의료 장치 회사로 내시경 검사에 첨단 에너지를 도입합니다.
회사의 비전은 Kamaptive가 지원하는 CROMA를 기반으로 하는 전기수술 의료기기 제품군의 개발 및 상용화를 통해 환자 결과를 개선하는 것입니다. 그룹은 수술 능력과 환자 결과를 최적화하기 위해 Kamaptive 전체 스펙트럼 적응 기술을 기반으로 하는 CROMA를 개발했습니다. Kamaptive는 조직 절제, 해부, 응고 및 절제와 같은 시술 중에 환자 조직에 동적으로 적응하도록 최적화된 다중 모드 에너지원의 원활하고 직관적인 통합입니다. Kamaptive 기술은 임상의에게 향상된 유연성, 정밀도 및 제어된 수술 솔루션을 제공합니다. CROMA는 현재 단일 액세서리 포트를 통해 정밀한 국소 절단을 위한 양극성 무선 주파수("RF") 에너지와 제어된 응고 및 절제를 위한 집중된 고주파 마이크로파("MW") 에너지를 제공합니다. 그룹의 다양한 특허 전기 수술 장치와 결합된 이 기술은 임상의에게 유연하고 정확하며 제어된 임상 솔루션을 제공하도록 설계되었습니다. 이사들은 회사의 기술이 보다 안전하고 덜 침습적이며 비용 효율적인 시술 옵션을 제공함으로써 수술 및 내시경 분야에 영향을 미칠 수 있다고 믿습니다.
자세한 내용은 홈페이지 www.creomedical.com을 참조하세요.
RNS는 귀하의 IP 주소를 사용하여 약관 준수 여부를 확인하고, 귀하가 이 커뮤니케이션에 포함된 정보를 사용하는 방식을 분석하고, 그러한 분석을 익명으로 다른 사람과 상용 서비스의 일부로 공유할 수 있습니다. RNS와 런던 증권 거래소가 귀하가 제공한 개인 데이터를 사용하는 방법에 대한 자세한 내용은 개인 정보 보호 정책을 참조하십시오.